• Home
  • About
  • Capabilities
  • R&D
  • Investors
  • News
  • Careers
简 繁
  • Home
  • About
  • Capabilities
  • R & D
  • Investors
  • News
  • Careers
Mabwell Signed an Agreement with Junshi Biosciences

Release time:Aug 28, 2017

The "Recombinant Human Anti-TNF-α Monoclonal Antibody Injection Cooperative Development Agreement" was signed with Shanghai Junshi Bio-pharmaceutical Co., Ltd. to jointly conduct preclinical research of a recombinant human anti-TNF-α monoclonal antibody injection.

Hot News
  • 2026 WOC | Mabwell to Present Latest Clinical Data on 9MW0211 for nAMD in Poster Presentations
  • 2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
  • Mabwell Lists on HKEX and Joins Stock Connect, Entering New Phase of Internationalization
  • 2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
  • Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
  • Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
  • About Who We Are Leadership Milestone Awards Contact
  • Capabilities R&D Manufacturing Commericalization
  • R&D Products Pipeline High-tech Platforms R&D Progress
  • Investors Stock Information Announcements & Notices Financial Report Corporate Governance IR Contact
  • News Press Release
  • Careers Value Awards & Welfare

Follow us
on WeChat

Copyright ©2022 Mabwell (Shanghai) Bioscience Co., Ltd. 沪 ICP 备 17041957 号 Shanghai public network security:31011502008788

Legal Statement| Privacy Policy| 技术支持:予尚网络